Meletios A. Dimopoulos, MD; Hagop Kantarjian, MD; Elihu Estey, MD; Susan O'Brien, MD; Kay Delasalle, BS; Michael J. Keating, MBBS; Emil J. Freireich, MD; Raymond Alexanian, MD
To evaluate the activity of 2-chlorodeoxyadenosine (2CdA) in the treatment of patients with Waldenstrom macroglobulinemia.
Uncontrolled phase II trial.
Tertiary, referral cancer center.
Twenty-nine consecutive, symptomatic patients with Waldenstrom macroglobulinemia, of whom 9 were previously untreated.
2-Chlorodeoxyadenosine was administered as a continuous intravenous infusion at a dose of 0.1 mg/kg body weight per day for 7 days. Only two courses of 2CdA were given and responding patients were then followed without further treatment.
A total of 17 (59%) patients responded, including all of those who were newly diagnosed and 40% of those who had failed previous therapies. Treatment was well tolerated except for one death in a patient who had presented with severe pancytopenia. With a median follow-up of 7 months, only one responding patient has relapsed.
2-Chlorodeoxyadenosine is a nucleoside analog that was effective in most patients with Waldenstrom macroglobulinemia and was associated with little toxicity.
Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, et al. Treatment of Waldenstrom Macroglobulinemia with 2-Chlorodeoxyadenosine. Ann Intern Med. ;118:195–198. doi: 10.7326/0003-4819-118-3-199302010-00007
Download citation file:
Published: Ann Intern Med. 1993;118(3):195-198.
Emergency Medicine, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use